Has anyone tried writing to them regarding the inter corporate loans/ deposits. There is a brief mention about it in a AGM recording available in their site, where they have made some vague remarks about it. They have mentioned that those are for certain future expansions and so.
As far as business is concerned cephalosporin seems to be the near term growth driver. Export to EU and Australia to contribute to Growth. Exports contributed to 60 % of sales in Q3. Export network to grow to 90 + countries from the current 60.
Its interesting to see stable margins in a tough environment.
LPL 2022-23 , Qtr.-3 Business Presentation.pdf (1.2 MB)
Link to recording: https://www.lincolnpharma.com/Investor/Disclosures%20under%20Regulation%2046%20of%20the%20LODR/14.%20AGM-EGM%20Results/2022-23/Transcript%20for%20AGM%202022.mp3?_t=1676715362
Discl: Have a small position and trying to understand better. May be biased.
| Subscribe To Our Free Newsletter |
